Edition:
United States

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

24.76EUR
11:35am EDT
Change (% chg)

€-0.20 (-0.80%)
Prev Close
€24.96
Open
€25.10
Day's High
€25.38
Day's Low
€24.70
Volume
33,827
Avg. Vol
123,394
52-wk High
€30.00
52-wk Low
€18.20

Chart for

About

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid... (more)

Overall

Beta: 1.26
Market Cap(Mil.): €896.62
Shares Outstanding(Mil.): 35.93
Dividend: --
Yield (%): --

Financials

  ALCLS.PA Industry Sector
P/E (TTM): -- 200.91 33.50
EPS (TTM): -2.35 -- --
ROI: -39.11 -0.75 13.17
ROE: -37.59 -2.86 14.98

BRIEF-Cellectis Announces Launch Of 175 Million Dollar Underwritten Public Offering Of Its American Depositary Shares

* ANNOUNCED ON WEDNESDAY LAUNCH OF FOLLOW-ON UNDERWRITTEN PUBLIC OFFERING OF $175 MLN OF ITS AMERICAN DEPOSITARY SHARES (ADS)

Apr 04 2018

Pfizer in deal with Allogene to develop cancer cell therapies

Pfizer Inc said on Tuesday it would take a 25 percent stake in Allogene Therapeutics to accelerate the development of CAR T cell therapies sourced from donors instead of patients.

Apr 03 2018

UPDATE 1-Pfizer in deal with Allogene to develop cancer cell therapies

April 3 Pfizer Inc said on Tuesday it would take a 25 percent stake in Allogene Therapeutics to accelerate the development of CAR T cell therapies sourced from donors instead of patients.

Apr 03 2018

Pfizer signs deal with Allogene to develop cancer cell therapy

April 3 Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake, to further develop its allogenic CAR T cell therapy.

Apr 03 2018

BRIEF-Cellectis Q4 Operating Loss Widens To 27.8 Million Dollars

* REPORTED ON MONDAY Q4 TOTAL REVENUES OF $6.9 MILLION VS $13.0 MILLION YR AGO

Mar 13 2018

France's Cellectis wins U.S patents for gene editing technology

PARIS The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

Feb 13 2018

France's Cellectis wins U.S patents for gene editing technology

PARIS, Feb 13 The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

Feb 13 2018

BRIEF-Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies

* SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Dec 13 2017

BRIEF-Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer

* CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Dec 04 2017

Earnings vs. Estimates